When bleeds happen, NovoSeven® RT provides your patients with:
2-5
5
minutes
hours
Rapid reconstitution1
Rapid administration1
Rapid bleed control3
16ϫ less infusion volume
than pd-aPCC1,4,b
Up to 18ϫ faster to infuse
than pd-aPCC1,4,b,c
Helps control joint bleeds
in as few as 5 hoursd,e
Products scaled
proportionally
from actual size.
Ask your local Novo Nordisk Representative for a free NovoSeven® RT Patient Starter Kit
Find your Rep at NovoSevenRT.com/hcp
Important Safety Information (cont’d)
Warnings and Precautions (cont’d)
• Exercise caution when administering NovoSeven® RT to patients with an increased risk of thromboembolic
complications, such as those with disseminated intravascular coagulation (DIC), advanced atherosclerotic disease, crush
injury, septicemia, uncontrolled post-partum hemorrhage, history of coronary heart disease, liver disease,
post-operative immobilization, in elderly patients, in neonates, or in patients receiving concomitant treatment
with aPCCs/PCCs (activated or nonactivated prothrombin complex concentrates).
• Hypersensitivity reactions, including anaphylaxis, have been reported with NovoSeven® RT. Administer only if clearly
needed in patients with known hypersensitivity to NovoSeven® RT, any of its components, or mouse, hamster, or
bovine proteins. Should symptoms occur, discontinue NovoSeven® RT and administer appropriate treatment.
• Factor VII deficient patients should be monitored for prothrombin time (PT) and factor VII coagulant activity (FVII:C).
If FVII:C fails to reach the expected level, or PT is not corrected, or bleeding is not controlled after treatment with the
recommended doses, antibody formation may be suspected and analysis for antibodies should be performed.
• Laboratory coagulation parameters (PT/INR, aPTT, FVII:C) have shown no direct correlation to achieving hemostasis.
Adverse Reactions
• The most common and serious adverse reactions in clinical trials are thrombotic events. Thrombotic adverse reactions
following the administration of NovoSeven® RT in clinical trials occurred in 4% of patients with acquired hemophilia
and 0.2% of bleeding episodes in patients with congenital hemophilia.
Drug Interactions
• Thrombosis may occur i